Orgenesis Inc. (NASDAQ:ORGS – Get Free Report) shot up 300% on Thursday . The company traded as high as $0.60 and last traded at $0.60. 100 shares were traded during trading, a decline of 84% from the average session volume of 636 shares. The stock had previously closed at $0.15.
Orgenesis Stock Performance
The business has a 50 day simple moving average of $0.28 and a 200-day simple moving average of $0.41. The stock has a market capitalization of $3.10 million, a P/E ratio of -0.08 and a beta of 3.44.
About Orgenesis
Orgenesis, Inc is a cell and gene therapy company that develops and commercializes point-of-care manufacturing platforms for autologous and allogeneic therapies. The company offers an end-to-end solution that spans from R&D through clinical and commercial production, targeting applications in oncology, neurology, and various rare diseases. Orgenesis’ technology platforms are designed to streamline the complex processes involved in cell isolation, genetic modification, expansion and cryopreservation.
The company’s flagship offering is its automated Prodigy® platform, which integrates cell processing workflows into a closed, single-use system.
See Also
- Five stocks we like better than Orgenesis
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- When to buy gold (mathematically)
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- GOLD ALERT
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
